Israeli cancer detection company Nucleix has announced positive results from a clinical study evaluating its cutting-edge Lung EpiCheck blood test for early detection of lung cancer. The Lung EpiCheck blood test is based on a proprietary molecular biomarker technology, which combines new biochemical assays and sophisticated algorithms. The technology is based on identification and analysis of subtle changes in DNA methylation patterns, which is a powerful tool for distinguishing between cancer and healthy cells and thus for detection of tumors in the body.
Go to the inbox of the email
address you just used to sign up.
Find the email sent by us. It has the subject line
“Nucleix: Please Confirm Subscription” and I
sent from “email@example.com”.
Click on the link inside the <br>email and you’re good to go.